Clinical Trial: Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above

U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT07481604) titled 'Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above' on March 13.

Brief Summary: To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.

Study Start Date: April, 2026

Study Type: INTERVENTIONAL

Condition: Herpes Zoster

Intervention: BIOLOGICAL: Shingrix

Licensed herpes zoster vaccine used as an active comparator.

BIOLOGICAL: CVI-VZV-001

Investigational herpes zoster vaccine.

Recruitment Status: NOT_YET_RECRUITING...